Research programme: dendritic cell vaccines - DanDrit Biotech

Drug Profile

Research programme: dendritic cell vaccines - DanDrit Biotech

Alternative Names: IndiCancerVac; Tolerogenic dendritic cell vaccine - Dandrit Biotech

Latest Information Update: 08 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator DanDrit Biotech A/S
  • Class Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Autoimmune disorders

Most Recent Events

  • 28 Sep 2016 Preclinical trials in Autoimmune disorders in Denmark (Parenteral) before September 2016 (DanDrit Biotech 10-K, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top